Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11546704 | 0.77 | CYP11B2 (0.56) | — | |
| SCHEMBL12026519 | 0.76 | ATM (0.33) | — | |
| SCHEMBL15907020 | 0.76 | PDE9A (0.40) | PDE9A | |
| SCHEMBL12049774 | 0.74 | CYP1A2 (0.41) | — | |
| SCHEMBL12533785 | 0.71 | CYP2A6 (0.33) | — | |
| SCHEMBL12533786 | 0.71 | CYP2A6 (0.33) | — | |
| SCHEMBL12533784 | 0.71 | CYP2A6 (0.33) | — | |
| SCHEMBL3719998 | 0.70 | HDAC4 (0.40) | — | |
| SCHEMBL18193689 | 0.70 | CHRM2 (0.38) | PDE9A | |
| SCHEMBL14930382 | 0.69 | TNKS (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2010131145-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | PDE9A 4/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | PDE9A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.